Press Releases

Press Releases

Oct 31, 2012
PISCATAWAY, NJ -- (Marketwire) -- 10/31/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2012.
Sep 11, 2012
PISCATAWAY, NJ -- (Marketwire) -- 09/11/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it will present at the 2012 World Congress and Expo on Biowaivers and Biosimilars , which is being held September 10-12 in San Antonio, TX.
Aug 1, 2012
PISCATAWAY, NJ -- (Marketwire) -- 08/01/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2012.
Jul 16, 2012
PISCATAWAY, NJ -- (Marketwire) -- 07/16/12 -- Enzon Pharmaceuticals, Inc.
Jun 19, 2012
PISCATAWAY, NJ -- (Marketwire) -- 06/19/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced the presentation of results from a Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors.
Jun 4, 2012
PISCATAWAY, NJ -- (MARKETWIRE) -- 06/04/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from the final analysis of a Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast cancer.
May 7, 2012
PISCATAWAY, NJ and ZHEJIANG, CHINA -- (Marketwire) -- 05/07/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) and Zhejiang Hisun Pharmaceuticals Co.
May 2, 2012
PISCATAWAY, NJ -- (Marketwire) -- 05/02/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the first quarter of 2012.
Mar 12, 2012
PISCATAWAY, NJ -- (MARKET WIRE) -- 03/12/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth-quarter and full-year 2011.
Dec 8, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 12/08/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from a Phase II, open-label study in which PEG-SN38 (EZN-2208) demonstrated notable activity in patients with previously treated metastatic breast cancer.